Related Experiment Video
Updated: May 27, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Mutant FLT3 signaling contributes to a block in myeloid differentiation
1Department of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Abstract:
FLT3 is a member of the class III receptor tyrosine kinase family and is primarily expressed on hematopoietic stem/progenitor cells. Somatic mutations of FLT3 involving internal tandem duplication (ITD) of the juxtamembrane domain or point mutations in the activation loop have been identified in approximately 17 - 34% and 7 - 9% of acute myeloid leukemia (AML) patients, respectively. The ITD mutations appear to activate the tyrosine kinase domain through receptor dimerization in a FLT3 ligand-independent manner. Constitutively activated FLT3 provides cells with proliferative and anti-apoptotic advantages and portends an especially poor prognosis for patients with this mutation. FLT3/ITD mutations also contribute to a block of myeloid differentiation. FLT3 tyrosine kinase inhibitors suppress the growth and induce apoptosis and differentiation of leukemia cells expressing FLT3/ITD mutants. Therefore, FLT3 is a therapeutic target and inhibition of FLT3 tyrosine kinase activity may provide a new approach in the treatment of leukemia carrying these mutations.
Insights
FMS-like tyrosine kinase 3 (FLT3) mutations, common in acute myeloid leukemia (AML), drive cancer growth. Inhibiting FLT3 offers a promising therapeutic strategy for AML patients with these mutations.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase crucial for hematopoietic stem/progenitor cell development.
- Somatic mutations in FLT3, including internal tandem duplications (ITD) and activation loop point mutations, are prevalent in acute myeloid leukemia (AML).
- FLT3/ITD mutations lead to ligand-independent receptor dimerization, constitutive kinase activation, and confer a poor prognosis in AML.
Purpose of the Study:
- To investigate the role of FLT3 mutations in AML pathogenesis.
- To evaluate FLT3 as a therapeutic target in AML.
- To explore the potential of FLT3 tyrosine kinase inhibitors in treating FLT3-mutated AML.
Main Methods:
- Analysis of FLT3 mutation status in AML patient cohorts.
- Investigating the molecular mechanisms of FLT3 activation by ITD mutations.
- Assessing the efficacy of FLT3 tyrosine kinase inhibitors in preclinical AML models.
Main Results:
- FLT3 mutations, particularly ITD, are associated with increased proliferation and resistance to apoptosis in leukemia cells.
- Constitutively active FLT3 signaling contributes to blocked myeloid differentiation in AML.
- FLT3 tyrosine kinase inhibitors demonstrate potent anti-leukemic activity, inducing apoptosis and differentiation in FLT3-mutated AML cells.
Conclusions:
- FLT3 is a critical oncogenic driver in a significant subset of AML.
- Targeting FLT3 kinase activity represents a viable therapeutic strategy for AML patients with FLT3 mutations.
- FLT3 inhibitors hold promise for improving treatment outcomes in FLT3-mutated AML.
